Adaptive Biotechnologies Corp ADPT
Adaptive Biotechnologies Corp (Nasdaq: ADPT) is an oncology diagnostics company. Its next catalyst on record is Corporate: Identify preferred path of separation of Immune Medicine and MRD businesses (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Corporate — Identify preferred path of separation of Immune Medicine and MRD businesses (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TCR-depleting antibody (autoimmunity) | Autoimmune disease | antibody | Pre-clinical |
| clonoSEQ (FDA de novo authorized MRD diagnostic; CLIA LDT for DLBCL/MCL) | Lymphoid malignancies MRD | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.